 Atai Life Sciences NV NASDAQ: ATAI has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression TRD and other mental health indications. 